Business
Santhera proposes Dr. Melanie Rolli as new member of Board of Directors
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, March 27, 2025 – Santhera Pharmaceuticals (SIX: SANN) proposes to elect Dr. Melanie Rolli as an Independent Director at the upcoming Annual General Meeting to be held on May 20, 2025. Current Board member Dr. Otto Schwarz will not stand for re-election. Thomas Meier, Chairman of the Board of Directors of Santhera, said: "We are delighted Dr. Rolli has agreed to be nominated to join the Board; where we believe she would bring exten
About this update from Santhera Pharmaceuticals Holding Ag
[{"type":"image","alt":"Santhera Pharmaceuticals Holding AG","displaySize":"","headline":null,"caption":"Santhera Pharmaceuticals Holding AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":235,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/69b76b9d28605c9cb06e9f424ed2d9b3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/m.yMU32TDRiiNbpVl.Y_mw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/69b76b9d28605c9cb06e9f424ed2d9b3","width":235,"height":71}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"Pratteln, Switzerland, March 27, 2025 – Santhera Pharmaceuticals (SIX: SANN) proposes to elect Dr. Melanie Rolli as an Independent Director at the upcoming Annual General Meeting to be held on May 20, 2025. Current Board member Dr. Otto Schwarz will not stand for re-election.","length":276,"tagName":"p"},{"type":"text","content":"Thomas Meier, Chairman of the Board of Directors of Santhera, said: "We are delighted Dr. Rolli has agreed to be nominated to join the Board; where we believe she would bring extensive strategic and operational expertise across drug development and commercialization. Her experience would be invaluable as we continue the rollout of AGAMREE® in new markets and evaluate opportunities to further expand our portfolio. Dr. Rolli’s nomination follows the recent appointment of Ms. Isted as CFO, reinforcing our commitment to strengthening and diversifying the Company’s Board and leadership team.","length":598,"tagName":"p"},{"type":"text","content":"On behalf of the Board and management I would additionally like to thank Dr. Schwarz for his great dedication and strong and valuable contribution to Santhera’s strategic development during his time as Board member. His guidance and expertise in the early phases of the AGAMREE® product launch was very helpful in setting the path for the Company’s commercial success.”","length":369,"tagName":"p"},{"type":"text","content":"Dr. Melanie Rolli is a seasoned biopharma executive with over 20 years international experience. She has held several executive and non-executive roles at various pharmaceutical and biotechnology companies and has a proven track record of product development and global commercialization. She is c...